Abstract Title:

L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis?

Abstract Source:

Int J Cardiol. 2007 Apr 4;116(3):300-8. Epub 2006 Jul 24. PMID: 16860889

Abstract Author(s):

Gerasimos Siasos, Dimitris Tousoulis, Charalambos Antoniades, Elli Stefanadi, Christodoulos Stefanadis

Article Affiliation:

Cardiology Unit, Hippokration Hospital, Athens University Medical School, S. Karagiorga 69, Glifada, 16 675, Athens, Greece.

Abstract:

L-Arginine is the substrate of endothelial nitric oxide synthase (eNOS) and the main precursor of nitric oxide (NO) in the vascular endothelium. L-Arginine improves endothelial function in patients with hypercholesterolemia, hypertension and smokers, while its role in diabetes remains unclear. Oral supplementation of L-arginine leads to a significant improvement of endothelium-dependent forearm vasodilation in hypercholesterolemic patients, while intravenous infusion of L-arginine improves endothelial function in healthy smokers. L-Arginine has anti-hypertensive properties, although its effects on endothelial function in hypertensive patients needs further evaluation. In conclusion, L-arginine administration may be useful in patients with premature atherosclerosis.

Pubmed Data : Int J Cardiol. 2007 Apr 4;116(3):300-8. Epub 2006 Jul 24. PMID: 16860889
Study Type : Human Study

Print Options

Login to Comment

Commenting is limited to Members only. If you are already a member, please login to post a comment. If you do not have a member account and would like to become a member, please click here to begin the process to become a member.

Post new comment

The content of this field is kept private and will not be shown publicly.
The subject field has a max length of 60 characters
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.